$354M ex­it pack­age in hand, Medi­va­tion CEO David Hung com­pletes a mas­ter class in biotech auc­tions

David Hung, Medi­va­tion CEO

Now that Medi­va­tion CEO David Hung has com­plet­ed the deal of a life­time with a stratos­pher­ic buy­out, he’s grab­bing a $35 mil­lion gold­en para­chute that is sched­uled to burst open in about a month and car­ry him back down to earth in style. And that’s part of a $354 mil­lion pack­age of stock and op­tions he can now cash out of.

The de­tails on the gold­en para­chute — along with a blow-by-blow ac­count of the bid­ding process that led up to Pfiz­er’s $14 bil­lion win­ner — were all in­clud­ed in an SEC fil­ing on Tues­day. And it makes for re­quired read­ing for any biotech ex­ec look­ing to make the big score some sun­ny day.

Oliv­er Brandi­court, Sanofi CEO

The game got start­ed in late March, when new Sanofi CEO Olivi­er Brandi­court con­tact­ed Hung and asked for a call. Days lat­er, the sto­ry was leaked to the busi­ness press, and Medi­va­tion was in play.

The re­view of what fol­lowed over the next few months in­cludes some in­ter­est­ing de­tails on Medi­va­tion’s re­sponse to Sanofi’s ini­tial low­ball of­fer. Nev­er hap­py with the open­ing bid, Medi­va­tion had an ace in the hole: Pfiz­er ex­ecs al­most im­me­di­ate­ly be­gan to ea­ger­ly vol­un­teer their in­ter­est to get in­to the auc­tion. And de­ter­mined to get top dol­lar, Medi­va­tion in­vit­ed more com­pa­nies to join Pfiz­er and Sanofi at the bar­gain­ing ta­ble.

To keep them en­gaged as the num­bers raced high­er, Medi­va­tion drew up a set of long range fi­nan­cial fore­casts for three dif­fer­ent sce­nar­ios in­volv­ing Xtan­di, its ap­proved can­cer drug, as well as its PARP in­hibitor ta­la­zoparib and an­oth­er mys­tery drug in the pipeline called pidilizum­ab, a can­cer treat­ment that Medi­va­tion ini­tial­ly thought was a check­point ther­a­py un­til it was forced to con­clude it wasn’t sure ex­act­ly what the mech­a­nism of ac­tion was. By the time the of­fers be­gan to fly, though, it bare­ly war­rant­ed a men­tion.

Un­der Medi­va­tion’s three sce­nar­ios, the com­pa­ny pro­ject­ed that its ex­pect­ed 2016 rev­enue of $922 mil­lion could peak at be­tween $5.7 bil­lion and $8.5 bil­lion in 2027, a lit­tle more than a decade away. And mean­while, he and the Medi­va­tion team con­duct­ed a pub­lic cam­paign to per­suade the in­dus­try that ta­la­zoparib was a cer­tain block­buster-to-be, ca­pa­ble of gen­er­at­ing more rev­enue than Xtan­di it­self.

It was all wild­ly over the top, but Hung was pulling out all the stops.

Near­ing the close of the auc­tion, Medi­va­tion set an Au­gust 20 dead­line for all fi­nal of­fers, net­ting Pfiz­er’s win­ning $81.50 bid along with two oth­ers for $80.25 and $80. For the mas­ter deal­mak­er, known for bag­ging ma­jor league col­lab­o­ra­tions that didn’t al­ways pan out, it was an un­mis­tak­able win.

For Pfiz­er, there are still years of ex­plain­ing ahead as it at­tempts to jus­ti­fy pay­ing a price many an­a­lysts thought was way too high.

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)

Pfiz­er makes an­oth­er bil­lion-dol­lar in­vest­ment in Eu­rope and ex­pands again in Michi­gan

Pfizer is continuing its run of manufacturing site expansions with two new large investments in the US and Europe.

The New York-based pharma giant’s site in Kalamazoo, MI, has seen a lot of attention over the past year. As a major piece of the manufacturing network for Covid-19 vaccines and antivirals, Pfizer is gearing up to place more money into the site. Pfizer announced it will place $750 million into the facility, mainly to establish “modular aseptic processing” (MAP) production and create around 300 jobs at the site.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images, Pool)

No­var­tis bol­sters Plu­vic­to's case in prostate can­cer with PhI­II re­sults

The prognosis is poor for metastatic castration-resistant prostate cancer (mCRPC) patients. Novartis wants to change that by making its recently approved Pluvicto available to patients earlier in their course of treatment.

The Swiss pharma giant unveiled Phase III results Monday suggesting that Pluvicto was able to halt disease progression in certain prostate cancer patients when administered after androgen-receptor pathway inhibitor (ARPI) therapy, but without prior taxane-based chemotherapy. The drug is currently approved for patients after they’ve received both ARPI and chemo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Yuling Li, Innoforce CEO

In­no­force opens new man­u­fac­tur­ing site in Chi­na

Innoforce is off to the races at its new site in the city of Hangzhou, China.

The Chinese CDMO announced last week that it has started manufacturing at the new facility, which was built to offer process development and manufacturing operations for RNA, plasmid DNA, viral vectors and other cell therapeutics. It will also serve as Innoforce’s corporate HQ.

The company said it’s investing more than $200 million in the 550,000-square-foot manufacturing base for advanced therapies. The GMP manufacturing facility features space for producing plasmids with three 30-liter bioreactors. For viral vector manufacturing, Innoforce also has 200- and 500-liter bioreactors at its disposal, along with eight suites to make cell therapies. The site also includes several labs and warehouse spaces.

FDA grants or­phan drug des­ig­na­tion to Al­ger­non's ifen­prodil, while ex­clu­siv­i­ty re­mains un­clear

As the FDA remains silent on orphan drug exclusivity in the wake of a controversial court case, the agency continues to hand out new designations. The latest: Algernon Pharmaceuticals’ experimental lung disease drug ifenprodil.

The Vancouver-based company announced on Monday that ifenprodil received orphan designation in idiopathic pulmonary fibrosis (IPF), a chronic lung condition that results in scarring of the lungs.  Most IPF patients suffer with a dry cough, and breathing can become difficult.

‘Catchy’ de­sign tops big ad buys on­line for grab­bing on­col­o­gists’ at­ten­tion — sur­vey

The cancer drug ads that get oncologists’ attention online are informative and use clear, eye-catching designs. That’s ZoomRx’s assessment in its most recent tracking survey, and while not necessarily surprising, the details in the research do break a few common misconceptions.

One of those is frequency, also known as the number of impressions an ad gets. No matter how many times oncologists saw a particular cancer drug ad, effectiveness prevailed in the survey across five drug brands. ZoomRx measured effectiveness as a combination of most attention-getting, relevant information and improved perception as reported by the doctors.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Tim Walbert, Horizon Therapeutics CEO (via YouTube)

And then there were two: Janssen bows out of Hori­zon takeover ne­go­ti­a­tions

Horizon Therapeutics announced last week that it was in talks with three pharmaceutical giants that could take over the company. You can now remove one of them from the equation.

J&J’s Janssen, after Horizon reported its initial involvement in early discussions to acquire the rare disease biotech, issued a statement Saturday that said Janssen “does not intend to make an offer for Horizon,” and that Janssen is bound by restrictions set in Rule 2.8 of the Irish Takeover Rules. These rules are in place for any company interested in taking over Irish companies, with Horizon Therapeutics currently based in Dublin.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Rick Modi, Affinia Therapeutics CEO

Ver­tex-part­nered gene ther­a­py biotech Affinia scraps IPO plans

Affinia Therapeutics has ditched its plans to go public in a relatively closed-door market that has not favored Nasdaq debuts for the drug development industry most of this year. A pandemic surge in 2020 and 2021 opened the doors for many preclinical startups, which caught Affinia’s attention and gave the gene therapy biotech confidence in the beginning days of 2022 to send in its S-1.

But on Friday, Affinia threw in the S-1 towel and concluded now is not the time to step onto Wall Street. The biotech has put out few public announcements since the spring of this year. Endpoints News picked the startup as one of its 11 biotechs to watch last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.